<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4630">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227655</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-302</org_study_id>
    <secondary_id>2010-022366-27</secondary_id>
    <secondary_id>BIA-91067-302</secondary_id>
    <nct_id>NCT01227655</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.</brief_title>
  <acronym>BIPARKII</acronym>
  <official_title>Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With &quot;Wearing-off&quot; Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Estonia: The State Agency of Medicine</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>India: Central Drugs Standard Control Organization</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an
      estimated incidence of 4.5-16/100,000 persons/year.

      BIA 9-1067 is currently being developed by BIAL (Portela &amp; Cª,S.A.) to be used in addition
      to L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients.
      Promising results have been obtained for BIA 9-1067 in previous studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to demonstrate the efficacy and safety of BIA 9-1067 used in addition to
      L-DOPA/DDCI to control the &quot;wearing-off&quot; phenomenon in patients with PD.

      DDCI (DOPA decarboxylase inhibitors): benserazide and carbidopa
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)</measure>
    <time_frame>14-15 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) compared with placebo, when administered with the existing treatment of L-DOPA plus a DDCI (DOPA decarboxylase inhibitor), in patients with PD and end-of-dose motor fluctuations. The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS (Unified Parkinson's Disease Rating Scale) Sections I (ON), II (ON and OFF), and III (ON)</measure>
    <time_frame>14-15 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total UPDRS SCORE (I, II (ON), and III) Change from Baseline to Endpoint
UPDRS I evaluation of mentation, behavior, and mood
UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food
UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.
Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe
The final cumulative score will range from 0 (no disability) to 199 (total disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Sleep Scale (PDSS)</measure>
    <time_frame>14-15 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Parkinson's disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.
Subscale has 0-10 ratings, where 0 = severe and 10 = normal
The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-motor Symptoms Scale (NMSS)</measure>
    <time_frame>14-15 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3
Frequency Rarely (&lt;1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4
The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.
The NMSS total score is calculated by adding all domain scores (0-360), and lower scores mean less disability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">427</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>BIA 9-1067 25 mg once daily (QD).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 50 mg once daily (QD).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLC, Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>Capsules will be used.</description>
    <arm_group_label>BIA 9-1067 25 mg once daily (QD).</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg once daily (QD).</arm_group_label>
    <other_name>Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>comparator</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo; PLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa</intervention_name>
    <arm_group_label>BIA 9-1067 25 mg once daily (QD).</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg once daily (QD).</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>L-Dopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa</intervention_name>
    <description>DOPA decarboxylase inhibitor (DDCI)</description>
    <arm_group_label>BIA 9-1067 25 mg once daily (QD).</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg once daily (QD).</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benserazide</intervention_name>
    <description>DOPA decarboxylase inhibitor</description>
    <arm_group_label>BIA 9-1067 25 mg once daily (QD).</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg once daily (QD).</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to comprehend and willing to sign an informed consent form.

          2. Male and female subjects between 30 and 83 years old, inclusive.

          3. Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain
             Bank Clinical Diagnostic Criteria for at least 3 years.

          4. Disease severity Stages I-III (modified Hoehn &amp;Yahr staging) at ON.

          5. Treated with L-DOPA/DDCI for at least 1 year with clear clinical improvement.

          6. Treated with 3 to 8 daily doses of L-DOPA/DDCI, which can include a slow-release
             formulation.

          7. On a stable regimen of L-DOPA/DDCI and other anti-PD drugs for at least 4 weeks
             before screening.

          8. Signs of &quot;wearing-off&quot; phenomenon (end-of-dose deterioration) for a minimum of 4
             weeks before screening with average total daily OFF time while awake of at least 1.5
             hours, excluding the early morning pre-first dose OFF, despite optimal anti-PD
             therapy (based on the investigator's judgment.

        Exclusion Criteria:

          1. Non-idiopathic PD (atypical parkinsonism, secondary [acquired or symptomatic]
             parkinsonism, Parkinson-plus syndrome).

          2. Dyskinesia disability score &gt;3 in the Unified Parkinson's Disease Rating Scale UPDRS)
             Sub-section IV A, item 33.

          3. Severe and/or unpredictable OFF periods.

          4. Treatment with prohibited medication: entacapone, tolcapone, neuroleptics,
             venlafaxine, MAO inhibitors (except selegiline up to 10 mg/day in oral formulation or
             1.25 mg/day in buccal absorption formulation or rasagiline up to 1mg/day), or
             antiemetics with antidopaminergic action (except domperidone) within the month before
             screening.

          5. Treatment with apomorphine within the month before screening or likely to be needed
             at any time during the study.

          6. Dosage change of concomitant anti-PD medication within 4 weeks of screening.

          7. Previous or planned (during the entire study duration, including the OL period)deep
             brain stimulation.

          8. Previous stereotactic surgery (e.g. pallidotomy, thalamotomy) for PD or with planned
             stereotactic surgery during the study period.

          9. Any investigational medicinal product within the 3 months (or within 5 half-lives,
             whichever is longer) before screening.

         10. Any medical condition that might place the subject at increased risk or interfere
             with assessments.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>83 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bial - Portela &amp; Cª, S.A.</name>
      <address>
        <city>S. Mamede do Coronado</city>
        <zip>4745-457</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 21, 2015</lastchanged_date>
  <firstreceived_date>October 22, 2010</firstreceived_date>
  <firstreceived_results_date>November 26, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>PD</keyword>
  <keyword>Wearing-off</keyword>
  <keyword>Levodopa/DDCI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIA 9-1067 25 mg</title>
          <description>BIA 9-1067 once daily (QD).</description>
        </group>
        <group group_id="P2">
          <title>BIA 9-1067 50 mg</title>
          <description>BIA 9-1067 once daily (QD).</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Four subjects from safety set who had no post-baseline OFF-time efficacy assessment were excluded from the full analysis set: three (1.9%) subjects in the OPC 50 mg group and one (0.7%) subject in the placebo group.</population>
      <group_list>
        <group group_id="B1">
          <title>BIA 9-1067 25 mg</title>
          <description>BIA 9-1067 once daily (QD).</description>
        </group>
        <group group_id="B2">
          <title>BIA 9-1067 50 mg</title>
          <description>BIA 9-1067 once daily (QD).</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: comparator</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="125"/>
                <measurement group_id="B2" value="147"/>
                <measurement group_id="B3" value="135"/>
                <measurement group_id="B4" value="407"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;70 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="96"/>
                <measurement group_id="B2" value="96"/>
                <measurement group_id="B3" value="107"/>
                <measurement group_id="B4" value="299"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>≥70 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="28"/>
                <measurement group_id="B4" value="108"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="82"/>
                <measurement group_id="B2" value="89"/>
                <measurement group_id="B3" value="71"/>
                <measurement group_id="B4" value="242"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="64"/>
                <measurement group_id="B4" value="165"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)</title>
        <description>Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) compared with placebo, when administered with the existing treatment of L-DOPA plus a DDCI (DOPA decarboxylase inhibitor), in patients with PD and end-of-dose motor fluctuations. The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period.</description>
        <time_frame>14-15 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 once daily (QD).</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 once daily (QD).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: comparator</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="135"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)</title>
            <description>Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) compared with placebo, when administered with the existing treatment of L-DOPA plus a DDCI (DOPA decarboxylase inhibitor), in patients with PD and end-of-dose motor fluctuations. The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period.</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-102.8" spread="159.42"/>
                  <measurement group_id="O2" value="-124.0" spread="178.23"/>
                  <measurement group_id="O3" value="-64.5" spread="155.35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS (Unified Parkinson’s Disease Rating Scale) Sections I (ON), II (ON and OFF), and III (ON)</title>
        <description>Total UPDRS SCORE (I, II (ON), and III) Change from Baseline to Endpoint
UPDRS I evaluation of mentation, behavior, and mood
UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food
UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.
Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe
The final cumulative score will range from 0 (no disability) to 199 (total disability).</description>
        <time_frame>14-15 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 once daily (QD).</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 once daily (QD).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: comparator</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="135"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>UPDRS (Unified Parkinson’s Disease Rating Scale) Sections I (ON), II (ON and OFF), and III (ON)</title>
            <description>Total UPDRS SCORE (I, II (ON), and III) Change from Baseline to Endpoint
UPDRS I evaluation of mentation, behavior, and mood
UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food
UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.
Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe
The final cumulative score will range from 0 (no disability) to 199 (total disability).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.8" spread="16.88"/>
                  <measurement group_id="O2" value="31.7" spread="17.55"/>
                  <measurement group_id="O3" value="31.5" spread="17.00"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Endpoint</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.6" spread="16.40"/>
                  <measurement group_id="O2" value="28.7" spread="18.11"/>
                  <measurement group_id="O3" value="28.1" spread="16.78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson’s Disease Sleep Scale (PDSS)</title>
        <description>The Parkinson’s disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.
Subscale has 0-10 ratings, where 0 = severe and 10 = normal
The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability.</description>
        <time_frame>14-15 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 once daily (QD).</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 once daily (QD).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: comparator</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="135"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Parkinson’s Disease Sleep Scale (PDSS)</title>
            <description>The Parkinson’s disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.
Subscale has 0-10 ratings, where 0 = severe and 10 = normal
The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95.75" spread="28.026"/>
                  <measurement group_id="O2" value="102.62" spread="25.116"/>
                  <measurement group_id="O3" value="101.76" spread="26.729"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="97.99" spread="26.196"/>
                  <measurement group_id="O2" value="103.05" spread="26.437"/>
                  <measurement group_id="O3" value="107.11" spread="26.987"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.79" spread="25.280"/>
                  <measurement group_id="O2" value="103.25" spread="26.752"/>
                  <measurement group_id="O3" value="105.39" spread="28.643"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-motor Symptoms Scale (NMSS)</title>
        <description>The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3
Frequency Rarely (&lt;1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4
The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.
The NMSS total score is calculated by adding all domain scores (0–360), and lower scores mean less disability.</description>
        <time_frame>14-15 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 25 mg</title>
            <description>BIA 9-1067 once daily (QD).</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 50 mg</title>
            <description>BIA 9-1067 once daily (QD).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: comparator</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="135"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Non-motor Symptoms Scale (NMSS)</title>
            <description>The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3
Frequency Rarely (&lt;1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4
The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.
The NMSS total score is calculated by adding all domain scores (0–360), and lower scores mean less disability.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38.2" spread="29.40"/>
                  <measurement group_id="O2" value="36.7" spread="30.88"/>
                  <measurement group_id="O3" value="38.2" spread="33.37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.7" spread="26.30"/>
                  <measurement group_id="O2" value="33.2" spread="27.95"/>
                  <measurement group_id="O3" value="33.5" spread="31.18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.0" spread="29.88"/>
                  <measurement group_id="O2" value="31.5" spread="28.47"/>
                  <measurement group_id="O3" value="31.6" spread="29.88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 9-1067 25 mg</title>
          <description>BIA 9-1067 once daily (QD).</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 50 mg</title>
          <description>BIA 9-1067 once daily (QD).</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BIOPSY PROSTATE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>DYSKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DELIRIUM FEBRILE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood CPK increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Parkinson’s disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
